NervGen Pharma Corp. Common stock
NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.02 | $0 | -$8M |
| 2025 Q4 | -0.44 | $0 | -$10M |
| 2025 Q3 | -0.06 | $0 | -$5M |
| 2025 Q2 | -0.13 | $0 | -$4M |
| 2025 Q1 | -0.06 | $0 | -$4M |
| 2024 Q4 | -0.12 | $0 | -$4M |
| 2024 Q3 |
| -0.08 |
| $0 |
| -$6M |
| 2024 Q2 | -0.11 | $0 | -$4M |